Date: 2017-07-26
Type of information: Capital increase
Company: Quantum Genomics (France)
Investors:
Amount: € 8.2 Million
Funding type: capital increase
Planned used: These funds will be used to support Quantum Genomics’ development programs, including the Phase II arterial hypertension study that will be launched in Fall 2017 in the United States. Called NEW-HOPE, this Phase II study is designed to assess the effectiveness of QGC001 on 250 high-risk hypertensive patients.
Others: • On July 26, 2017, Quantum Genomics announced that it has completed a placement and capital increase, including the removal of preferential subscription rights, reserved for a category of beneficiaries. In this placement, the Company issued 2,191,698 ordinary shares at €3.75 per share, and warrants with a term of 30 months to purchase up to 1,643,774 additional ordinary shares at an exercise price of €4.75 per share. This €8.2 Million fundraising may be increased to €16.0 Million if all of the share purchase warrants were to be exercised.
Therapeutic area: Cardiovascular diseases
